Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 5/2016

19.08.2016

Prevention of Contrast-Induced Acute Kidney Injury: an Update

verfasst von: George Chalikias, Ioannis Drosos, Dimitrios N. Tziakas

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Contrast-induced acute kidney injury (CI-AKI) is a common complication of intravascular administration of contrast media used in coronary angiography, percutaneous coronary intervention and other diagnostic and interventional procedures. This review article aims at summarizing the published literature regarding the prevention of CI-AKI, by focusing on available high-quality meta-analyses addressing this matter. Apart from adequate hydration, a number of pharmacologic agents have been proposed as potential candidates to be included in the routine preparation, prior to the patient’s arrival in the cardiac catheterization laboratory. Among them, statins and N-acetylcysteine appear to be the most extensively studied ones. Throughout this article we present the available data on CI-AKI prevention and provide a critical clinical appraisal, as well as a summary of currently available guidelines.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMed Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMed
2.
Zurück zum Zitat Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol. 2008;21(1):74–85.CrossRefPubMed Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol. 2008;21(1):74–85.CrossRefPubMed
3.
Zurück zum Zitat Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9.CrossRefPubMed Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9.CrossRefPubMed
4.
Zurück zum Zitat James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: A systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(1):37–43.CrossRefPubMed James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: A systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(1):37–43.CrossRefPubMed
5.
Zurück zum Zitat Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–7.CrossRefPubMed Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–7.CrossRefPubMed
6.
Zurück zum Zitat Oduncu V, Erkol A, Karabay CY, Sengul C, Tanalp AC, Fotbolcu H, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol. 2013;168(4):3480–5.CrossRefPubMed Oduncu V, Erkol A, Karabay CY, Sengul C, Tanalp AC, Fotbolcu H, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol. 2013;168(4):3480–5.CrossRefPubMed
7.
Zurück zum Zitat Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. 2016. Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther. 2016.
8.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter, Suppl. 2012;2(1):1-138. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter, Suppl. 2012;2(1):1-138.
9.
Zurück zum Zitat Jurado-Roman A, Hernandez-Hernandez F, Garcia-Tejada J, Granda-Nistal C, Molina J, Velazquez M, et al. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol. 2015;115(9):1174–8.CrossRefPubMed Jurado-Roman A, Hernandez-Hernandez F, Garcia-Tejada J, Granda-Nistal C, Molina J, Velazquez M, et al. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol. 2015;115(9):1174–8.CrossRefPubMed
10.
Zurück zum Zitat Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329–36.CrossRefPubMed Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329–36.CrossRefPubMed
11.
Zurück zum Zitat Lindinger MI, Franklin TW, Lands LC, Pedersen PK, Welsh DG, Heigenhauser GJ. NaHCO(3) and KHCO(3) ingestion rapidly increases renal electrolyte excretion in humans. J Appl Physiol (1985). 2000;88(2):540–550. Lindinger MI, Franklin TW, Lands LC, Pedersen PK, Welsh DG, Heigenhauser GJ. NaHCO(3) and KHCO(3) ingestion rapidly increases renal electrolyte excretion in humans. J Appl Physiol (1985). 2000;88(2):540–550.
12.
Zurück zum Zitat Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–34.CrossRefPubMed Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–34.CrossRefPubMed
13.
Zurück zum Zitat Zhang B, Liang L, Chen W, Liang C, Zhang S. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis. BMJ Open. 2015;5(3):e006989. Zhang B, Liang L, Chen W, Liang C, Zhang S. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis. BMJ Open. 2015;5(3):e006989.
14.
Zurück zum Zitat Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010;25(3):747–58.CrossRefPubMed Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010;25(3):747–58.CrossRefPubMed
15.
Zurück zum Zitat Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23.
16.
Zurück zum Zitat Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury - A systematic review and meta-analysis. Circ J. 2012;76(9):2255–65.CrossRefPubMed Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH, et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury - A systematic review and meta-analysis. Circ J. 2012;76(9):2255–65.CrossRefPubMed
17.
Zurück zum Zitat Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol. 2011;79(1):48–55.CrossRefPubMed Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol. 2011;79(1):48–55.CrossRefPubMed
18.
Zurück zum Zitat Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(4):617–27.CrossRefPubMed Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(4):617–27.CrossRefPubMed
19.
Zurück zum Zitat Gu G, Zhang Y, Lu R, Cui W. Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(1):387–94.PubMedPubMedCentral Gu G, Zhang Y, Lu R, Cui W. Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(1):387–94.PubMedPubMedCentral
20.
Zurück zum Zitat Duan N, Zhao J, Li Z, Dong P, Wang S, Zhao Y, et al. Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: A meta-analysis of randomized controlled trials. Med Sci Monit. 2015;21:292–7.CrossRefPubMedPubMedCentral Duan N, Zhao J, Li Z, Dong P, Wang S, Zhao Y, et al. Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: A meta-analysis of randomized controlled trials. Med Sci Monit. 2015;21:292–7.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Yang B, Xu J, Xu F, Zou Z, Ye C, Mei C, et al. Intravascular administration of mannitol for acute kidney injury prevention: A systematic review and meta-analysis. PLoS One. 2014;9(1):e85029.CrossRefPubMedPubMedCentral Yang B, Xu J, Xu F, Zou Z, Ye C, Mei C, et al. Intravascular administration of mannitol for acute kidney injury prevention: A systematic review and meta-analysis. PLoS One. 2014;9(1):e85029.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Dorval JF, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS. Feasibility study of the RenalGuard balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol. 2013;166(2):482–6.CrossRefPubMed Dorval JF, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS. Feasibility study of the RenalGuard balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Int J Cardiol. 2013;166(2):482–6.CrossRefPubMed
23.
Zurück zum Zitat Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–9.CrossRefPubMed Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–9.CrossRefPubMed
24.
Zurück zum Zitat Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.CrossRefPubMed Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.CrossRefPubMed
25.
Zurück zum Zitat Briguori C, Visconti G, Donahue M, De Micco F, Focaccio A, Golia B, et al. RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Am Heart J. 2016;173:67–76.CrossRefPubMed Briguori C, Visconti G, Donahue M, De Micco F, Focaccio A, Golia B, et al. RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Am Heart J. 2016;173:67–76.CrossRefPubMed
26.
Zurück zum Zitat Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: The POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–23.CrossRefPubMed Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: The POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–23.CrossRefPubMed
27.
Zurück zum Zitat Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients. JACC Cardiovasc Interv. 2016;9(1):89–96.CrossRefPubMed Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients. JACC Cardiovasc Interv. 2016;9(1):89–96.CrossRefPubMed
28.
Zurück zum Zitat Maioli M, Toso A, Leoncini M, Musilli N, Bellandi F, Rosner MH, et al. Pre-procedural bioimpedance vectorial analysis of fluid status and prediction of contrast-induced acute kidney injury. J Am Coll Cardiol. 2014;63(14):1387–94.CrossRefPubMed Maioli M, Toso A, Leoncini M, Musilli N, Bellandi F, Rosner MH, et al. Pre-procedural bioimpedance vectorial analysis of fluid status and prediction of contrast-induced acute kidney injury. J Am Coll Cardiol. 2014;63(14):1387–94.CrossRefPubMed
30.
Zurück zum Zitat Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295(1):F53–9.CrossRefPubMedPubMedCentral Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295(1):F53–9.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273–8.CrossRefPubMed Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273–8.CrossRefPubMed
32.
Zurück zum Zitat Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843–9.CrossRefPubMed Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843–9.CrossRefPubMed
33.
Zurück zum Zitat Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, AL. B. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015;183:47–53.CrossRefPubMed Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, AL. B. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015;183:47–53.CrossRefPubMed
34.
Zurück zum Zitat Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol. 2014;114(4):541–8.CrossRefPubMed Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol. 2014;114(4):541–8.CrossRefPubMed
35.
Zurück zum Zitat Ukaigwe A, Karmacharya P, Mahmood M, Pathak R, Aryal MR, Jalota L, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol. 2014;114(9):1295–302.CrossRefPubMed Ukaigwe A, Karmacharya P, Mahmood M, Pathak R, Aryal MR, Jalota L, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol. 2014;114(9):1295–302.CrossRefPubMed
36.
Zurück zum Zitat Briasoulis A, Mallikethi-Reddy S, Sharma S, Briasouli AA, Afonso L. 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies. Am J Ther. 2015;22(6):e158–66.CrossRefPubMed Briasoulis A, Mallikethi-Reddy S, Sharma S, Briasouli AA, Afonso L. 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies. Am J Ther. 2015;22(6):e158–66.CrossRefPubMed
37.
Zurück zum Zitat Liu YH, Liu Y, Duan CY, Tan N, Chen JY, Zhou YL, et al. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(2):181–92.CrossRefPubMed Liu YH, Liu Y, Duan CY, Tan N, Chen JY, Zhou YL, et al. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(2):181–92.CrossRefPubMed
38.
Zurück zum Zitat Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, et al. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: Updated study-level meta-analysis of 13 randomized controlled trials. PLoS One. 2014;9(11):e111397.CrossRefPubMedPubMedCentral Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, et al. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: Updated study-level meta-analysis of 13 randomized controlled trials. PLoS One. 2014;9(11):e111397.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Xie H, Ye Y, Shan G, Zhang S, Fang Q, Yang D, et al. Effect of statins in preventing contrast-induced nephropathy: An updated meta-analysis. Coron Artery Dis. 2014;25(7):565–74.CrossRefPubMed Xie H, Ye Y, Shan G, Zhang S, Fang Q, Yang D, et al. Effect of statins in preventing contrast-induced nephropathy: An updated meta-analysis. Coron Artery Dis. 2014;25(7):565–74.CrossRefPubMed
40.
Zurück zum Zitat Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy. 2005;25(8):1095–103.CrossRefPubMed Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy. 2005;25(8):1095–103.CrossRefPubMed
41.
Zurück zum Zitat Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–4.CrossRefPubMed Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–4.CrossRefPubMed
42.
Zurück zum Zitat Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136–41.CrossRefPubMed Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136–41.CrossRefPubMed
43.
Zurück zum Zitat Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J. 2004;148(3):422–9.CrossRefPubMed Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J. 2004;148(3):422–9.CrossRefPubMed
44.
Zurück zum Zitat O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013;64(8):576–82.CrossRefPubMed O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013;64(8):576–82.CrossRefPubMed
45.
Zurück zum Zitat MY W, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, et al. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: A meta-analysis of randomized controlled trials. Int Urol Nephrol. 2013;45(5):1309–18.CrossRef MY W, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, et al. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: A meta-analysis of randomized controlled trials. Int Urol Nephrol. 2013;45(5):1309–18.CrossRef
46.
Zurück zum Zitat Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013;8(1):e55124.CrossRefPubMedPubMedCentral Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013;8(1):e55124.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140–5.CrossRefPubMed Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151(1):140–5.CrossRefPubMed
48.
Zurück zum Zitat Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2004;2:38. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2004;2:38.
49.
Zurück zum Zitat Jacobs C, Hutton B, Ng T, Shorr R. Clemons M. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015;20(2):210–23.CrossRefPubMedPubMedCentral Jacobs C, Hutton B, Ng T, Shorr R. Clemons M. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist. 2015;20(2):210–23.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Arrigoni O, De Tullio MC. Ascorbic acid: Much more than just an antioxidant. Biochim Biophys Acta 2002;1569(1–3):1–9. Arrigoni O, De Tullio MC. Ascorbic acid: Much more than just an antioxidant. Biochim Biophys Acta 2002;1569(1–3):1–9.
51.
Zurück zum Zitat Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837–42.CrossRefPubMed Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837–42.CrossRefPubMed
52.
Zurück zum Zitat Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167–75.CrossRefPubMed Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167–75.CrossRefPubMed
53.
Zurück zum Zitat Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45(5):1425–31.CrossRefPubMed Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45(5):1425–31.CrossRefPubMed
54.
Zurück zum Zitat Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2012;60(3):360–70.CrossRefPubMed Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2012;60(3):360–70.CrossRefPubMed
55.
Zurück zum Zitat Akgullu C, Saruhan T, Eryilmaz U, Boyacioglu M, Onbasili OA, Meteoglu I, et al. The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy. Ren Fail. 2014;36(4):575–80.CrossRefPubMed Akgullu C, Saruhan T, Eryilmaz U, Boyacioglu M, Onbasili OA, Meteoglu I, et al. The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy. Ren Fail. 2014;36(4):575–80.CrossRefPubMed
56.
Zurück zum Zitat Ozden A, Aybek Z, Saydam N, Calli N, Saydam O, Duzcan E, et al. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury in rats. Eur Surg Res. 1998;30(4):227–34.CrossRefPubMed Ozden A, Aybek Z, Saydam N, Calli N, Saydam O, Duzcan E, et al. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury in rats. Eur Surg Res. 1998;30(4):227–34.CrossRefPubMed
57.
Zurück zum Zitat Nadkarni GN, Konstantinidis I, Patel A, Yacoub R, Kumbala D, Patel RA, et al. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(6):539–46.CrossRefPubMed Nadkarni GN, Konstantinidis I, Patel A, Yacoub R, Kumbala D, Patel RA, et al. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(6):539–46.CrossRefPubMed
58.
Zurück zum Zitat Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, et al. The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention. J Cardiovasc Pharmacol Ther. 2014;19(3):310–4.CrossRefPubMed Peguero JG, Cornielle V, Gomez SI, Issa OM, Heimowitz TB, Santana O, et al. The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention. J Cardiovasc Pharmacol Ther. 2014;19(3):310–4.CrossRefPubMed
59.
Zurück zum Zitat Nichols AJ, Ruffolo RR, Jr., Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990;3(6 Pt 2):116s–9s. Nichols AJ, Ruffolo RR, Jr., Brooks DP. The pharmacology of fenoldopam. Am J Hypertens. 1990;3(6 Pt 2):116s–9s.
60.
Zurück zum Zitat Talati S, Kirtane AJ, Hassanin A, Mehran R, Leon MB, Moses JW, et al. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk. Clin Exp Pharmacol Physiol. 2012;39(6):506–9.CrossRefPubMed Talati S, Kirtane AJ, Hassanin A, Mehran R, Leon MB, Moses JW, et al. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk. Clin Exp Pharmacol Physiol. 2012;39(6):506–9.CrossRefPubMed
61.
Zurück zum Zitat Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, et al. Intravenous magnesium sulfate: New method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol. 2015;47(3):521–5.CrossRefPubMed Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, et al. Intravenous magnesium sulfate: New method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol. 2015;47(3):521–5.CrossRefPubMed
62.
Zurück zum Zitat Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, et al. Protective effect of apocynin, A NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol. 2012;674(2–3):397–406.CrossRefPubMed Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, et al. Protective effect of apocynin, A NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol. 2012;674(2–3):397–406.CrossRefPubMed
63.
Zurück zum Zitat Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012;23(4):265–70.CrossRefPubMed Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012;23(4):265–70.CrossRefPubMed
64.
Zurück zum Zitat Markota D, Markota I, Starcevic B, Tomic M, Prskalo Z, Brizic I. Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J. 2013;34(30):2362–7.CrossRefPubMed Markota D, Markota I, Starcevic B, Tomic M, Prskalo Z, Brizic I. Prevention of contrast-induced nephropathy with Na/K citrate. Eur Heart J. 2013;34(30):2362–7.CrossRefPubMed
65.
Zurück zum Zitat Koch C, Chaudru S, Lederlin M, Jaquinandi V, Kaladji A, Mahe G. Remote ischemic preconditioning and contrast-induced nephropathy: a systematic review. Ann Vasc Surg. 2016. Koch C, Chaudru S, Lederlin M, Jaquinandi V, Kaladji A, Mahe G. Remote ischemic preconditioning and contrast-induced nephropathy: a systematic review. Ann Vasc Surg. 2016.
66.
Zurück zum Zitat Menting TP, Sterenborg TB, de Waal Y, Donders R, Wever KE, Lemson MS, et al. Remote Ischemic Preconditioning To Reduce Contrast-Induced Nephropathy: A randomized controlled trial. Eur J Vasc Endovasc Surg. 2015;50(4):527–32.CrossRefPubMed Menting TP, Sterenborg TB, de Waal Y, Donders R, Wever KE, Lemson MS, et al. Remote Ischemic Preconditioning To Reduce Contrast-Induced Nephropathy: A randomized controlled trial. Eur J Vasc Endovasc Surg. 2015;50(4):527–32.CrossRefPubMed
67.
Zurück zum Zitat Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: Randomized pilot RenPro trial (renal protection trial). Circulation 2012;126(3):296–303. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: Randomized pilot RenPro trial (renal protection trial). Circulation 2012;126(3):296–303.
68.
Zurück zum Zitat Sekiguchi H, Ajiro Y, Uchida Y, Ishida I, Otsuki H, Hattori H, et al. Oxygen pre-conditioning prevents contrast-induced nephropathy (OPtion CIN Study). J Am Coll Cardiol. 2013;62(2):162–3.CrossRefPubMed Sekiguchi H, Ajiro Y, Uchida Y, Ishida I, Otsuki H, Hattori H, et al. Oxygen pre-conditioning prevents contrast-induced nephropathy (OPtion CIN Study). J Am Coll Cardiol. 2013;62(2):162–3.CrossRefPubMed
69.
Zurück zum Zitat Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012;125(1):66–78.e3. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012;125(1):66–78.e3.
70.
Zurück zum Zitat Duffy SJ, Ruygrok P, Juergens CP, Sievert H, Richards M, Blake J, et al. Removal of contrast media from the coronary sinus attenuates renal injury after coronary angiography and intervention. J Am Coll Cardiol. 2010;56(6):525–6.CrossRefPubMed Duffy SJ, Ruygrok P, Juergens CP, Sievert H, Richards M, Blake J, et al. Removal of contrast media from the coronary sinus attenuates renal injury after coronary angiography and intervention. J Am Coll Cardiol. 2010;56(6):525–6.CrossRefPubMed
71.
Zurück zum Zitat Watson T, Burd JS, Ruygrok PN. Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral vein. Int J Cardiol. 2013;165(1):e9–10.CrossRefPubMed Watson T, Burd JS, Ruygrok PN. Prevention of contrast induced nephropathy during coronary angiography with a coronary sinus contrast removal system sited from the femoral vein. Int J Cardiol. 2013;165(1):e9–10.CrossRefPubMed
72.
Zurück zum Zitat Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol. 2014;113(1):49–53.CrossRefPubMed Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol. 2014;113(1):49–53.CrossRefPubMed
73.
Zurück zum Zitat Kaye DM, Stub D, Mak V, Doan T, Duffy SJ. Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography. Catheter Cardiovasc Interv. 2014;83(5):741–5.CrossRefPubMed Kaye DM, Stub D, Mak V, Doan T, Duffy SJ. Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography. Catheter Cardiovasc Interv. 2014;83(5):741–5.CrossRefPubMed
74.
Zurück zum Zitat Prasad A, Ortiz-Lopez C, Kaye DM, Byrne M, Nanayakkara S, Ahmed SH, et al. The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheter Cardiovasc Interv. 2015;86(7):1228–33.CrossRefPubMed Prasad A, Ortiz-Lopez C, Kaye DM, Byrne M, Nanayakkara S, Ahmed SH, et al. The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheter Cardiovasc Interv. 2015;86(7):1228–33.CrossRefPubMed
76.
Zurück zum Zitat Malik A. Prevention of contrast-induced acute kidney injury. Br J Hosp Med (Lond). 2015;76(12):685–9.CrossRef Malik A. Prevention of contrast-induced acute kidney injury. Br J Hosp Med (Lond). 2015;76(12):685–9.CrossRef
77.
Zurück zum Zitat Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, et al. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: A propensity-matched study. Am J Kidney Dis. 2012;60(4):576–82.CrossRefPubMed Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, et al. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: A propensity-matched study. Am J Kidney Dis. 2012;60(4):576–82.CrossRefPubMed
78.
Zurück zum Zitat Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, et al. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015;170(1):110–6.CrossRefPubMed Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, et al. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015;170(1):110–6.CrossRefPubMed
79.
Zurück zum Zitat Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65(2):96–105. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65(2):96–105.
80.
Zurück zum Zitat Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–9.CrossRefPubMed Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–9.CrossRefPubMed
81.
Zurück zum Zitat Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2012. 2011;79(3):453–95.CrossRef Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2012. 2011;79(3):453–95.CrossRef
82.
Zurück zum Zitat Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014. 2014;35(37):2541–619. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014. 2014;35(37):2541–619.
Metadaten
Titel
Prevention of Contrast-Induced Acute Kidney Injury: an Update
verfasst von
George Chalikias
Ioannis Drosos
Dimitrios N. Tziakas
Publikationsdatum
19.08.2016
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2016
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6683-0

Weitere Artikel der Ausgabe 5/2016

Cardiovascular Drugs and Therapy 5/2016 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.